Information  X 
Enter a valid email address

CareTech Holdings (CTH)

  Print      Mail a friend

Friday 15 May, 2020

CareTech Holdings

Appointment of Joint Corporate Broker

RNS Number : 9857M
CareTech Holdings PLC
15 May 2020
 

15 May 2020

 

CareTech Holdings PLC

 

("CareTech" or the "Group")

 

 

Appointment of Joint Corporate Broker

 

CareTech Holdings PLC (AIM: CTH), a pioneering provider of specialist social care and education services to adults and children in the UK , announces the appointment of Numis as the Group's joint corporate broker with immediate effect. Panmure Gordon will continue to act as the Group's Nominated Adviser and joint corporate broker.

 

For further information, please contact:

CareTech Holdings PLC

Farouq Sheikh, Executive Chairman

Christopher Dickinson, Group Finance Director

 

01707 601800

Consilium Strategic Communications

Mary-Jane Elliott

Chris Welsh

Angela Gray

020 3709 5700

Panmure Gordon (Nomad and Joint Broker)

Emma Earl

Freddy Crossley

Charles Leigh-Pemberton

020 7886 2500

Numis (Joint Broker)

Jonathan Wilcox

James Black

Duncan Monteith

--------------------------------------------------------------

020 7260 1000

 

About CareTech

CareTech Holdings PLC is a leading provider of specialist social care and education services, supporting around 4,500 adults and children with a wide range of complex needs in more than 550 residential facilities and specialist schools around the UK and employing approximately 10,000 staff.

Committed to the highest standards of care and care governance, CareTech provides its innovative care pathways covering; Adult learning disabilities and specialist services; Children's residential and education services; and foster care.

CareTech, which was founded in 1993, began trading on the AIM market of the London Stock Exchange in October 2005 under the ticker symbol CTH.

For further information please visit:  www.caretech-uk.com

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
APPFFFVLERISLII

a d v e r t i s e m e n t